Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma
In a phase 3 double-blind trial, 1137 patients with completely resected high-risk cutaneous melanoma had recurrence-free survival at 24 months of 82.2% with the individualized neoantigen therapy intismeran plus pembrolizumab versus 70.0% with pembrolizumab alone, and distant-metastasis-free survival of 88.5% versus 80.2%.
New England Journal of Medicine · 10.1056/nejmoa2609762